Forest Laboratories, J&J sales and marketing update

Forest's Forest Laboratories Holdings Ltd. subsidiary granted Johnson & Johnson's Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals Inc. units exclusive Canadian rights to Bystolic nebivolol and Savella milnacipran, respectively. Forest will receive an undisclosed upfront payment and is eligible for milestones and royalties. As part of the deal, the J&J units will sublicense the rights to Janssen Inc., a division of J&J. Jansen will be responsible for regulatory approval in Canada. Forest will have the opportunity to co-promote after the first anniversary of regulatory approval for either product. ...